EP3773523A4 - Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite - Google Patents

Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite Download PDF

Info

Publication number
EP3773523A4
EP3773523A4 EP19776042.4A EP19776042A EP3773523A4 EP 3773523 A4 EP3773523 A4 EP 3773523A4 EP 19776042 A EP19776042 A EP 19776042A EP 3773523 A4 EP3773523 A4 EP 3773523A4
Authority
EP
European Patent Office
Prior art keywords
metabolite
methods
therapeutic agent
agent based
measured levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19776042.4A
Other languages
German (de)
French (fr)
Other versions
EP3773523A1 (en
Inventor
Vikram S. Kumar
David P. Hesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clear Creek Bio Inc
Original Assignee
Clear Creek Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clear Creek Bio Inc filed Critical Clear Creek Bio Inc
Publication of EP3773523A1 publication Critical patent/EP3773523A1/en
Publication of EP3773523A4 publication Critical patent/EP3773523A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
EP19776042.4A 2018-03-26 2019-03-26 Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite Withdrawn EP3773523A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862648320P 2018-03-26 2018-03-26
US201862655407P 2018-04-10 2018-04-10
US201862682419P 2018-06-08 2018-06-08
US201862682427P 2018-06-08 2018-06-08
US201862682411P 2018-06-08 2018-06-08
PCT/US2019/023983 WO2019191030A1 (en) 2018-03-26 2019-03-26 Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite

Publications (2)

Publication Number Publication Date
EP3773523A1 EP3773523A1 (en) 2021-02-17
EP3773523A4 true EP3773523A4 (en) 2021-12-29

Family

ID=68058448

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19776042.4A Withdrawn EP3773523A4 (en) 2018-03-26 2019-03-26 Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite

Country Status (5)

Country Link
EP (1) EP3773523A4 (en)
JP (1) JP2021519338A (en)
AU (1) AU2019242626A1 (en)
CA (1) CA3094104A1 (en)
WO (1) WO2019191030A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
TW202104207A (en) 2019-04-17 2021-02-01 美商健生生物科技公司 Dihydroorotate dehydrogenase inhibitors
US20210292406A1 (en) * 2020-03-18 2021-09-23 Flow Pharma, Inc. Controlled release of antibodies to modulate cytokines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017037022A1 (en) * 2015-09-01 2017-03-09 Bayer Pharma Aktiengesellschaft Compounds and methods useful for treating or preventing hematological cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US11458126B2 (en) * 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017037022A1 (en) * 2015-09-01 2017-03-09 Bayer Pharma Aktiengesellschaft Compounds and methods useful for treating or preventing hematological cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAKOWKA L ET AL: "THE DEVELOPMENT OF BREQUINAR AS AN IMMUNOSUPPRESSIVE DRUG FOR TRANSPLANTATION", IMMUNOLOGICAL REVIEWS, WILEY-BLACKWELL PUBLISHING, INC, US, no. 136, 1 January 1993 (1993-01-01), pages 51 - 70, XP001008068, ISSN: 0105-2896, DOI: 10.1111/J.1600-065X.1993.TB00654.X *
MONTSE ERRA ET AL: "Biaryl analogues of teriflunomide as potent DHODH inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 24, 14 October 2011 (2011-10-14), pages 7268 - 7272, XP028113869, ISSN: 0960-894X, [retrieved on 20111020], DOI: 10.1016/J.BMCL.2011.10.052 *
See also references of WO2019191030A1 *

Also Published As

Publication number Publication date
AU2019242626A1 (en) 2020-09-24
WO2019191030A1 (en) 2019-10-03
CA3094104A1 (en) 2019-10-03
JP2021519338A (en) 2021-08-10
EP3773523A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
EP3729381A4 (en) Viewpoint dependent brick selection for fast volumetric reconstruction
SG11202107286PA (en) Early measurement reporting
EP3850386A4 (en) Method and system for in-vivo, and non-invasive measurement of metabolite levels
EP3773523A4 (en) Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite
EP3596448A4 (en) Method for improving usability and accuracy for physiological measurement
EP3684292A4 (en) User interface for a dental measurement system
GB2589673B (en) Level measurement instrument
EP3160521A4 (en) Sampling apparatus for determining the amount and uniformity of a delivered dose of drug related methods
PL3923971T3 (en) Analyzing the effect of a polyribonucleotide on ciliogenesis
EP3805795A4 (en) Time measurement device
DK4061453T3 (en) DRY POWDER INHALER WITH AN ADHERENCE/COMPLIANCE MONITOR
EP3821209A4 (en) Measured dose dispenser and methods of using the same
CA185499S (en) Tape measure
EP4053512A4 (en) Propagation time measurement device
IL279412A (en) Device for measuring distances
EP3967222A4 (en) Respiration measurement device
PL3742144T3 (en) Measuring device
EP3845854A4 (en) Length measuring device, length measuring method, program, and body height meter
EP3921763A4 (en) Determining the location of an animal
EP3551053A4 (en) Health and fitness monitor for determining a minimum heart rate
EP4031005C0 (en) System for determining an emotion of a user
EP3789790C0 (en) Distance measuring device
EP3974105A4 (en) Measurement device
EP3992593A4 (en) Combined measurement device
GB2583714B (en) Non-Invasive Measurement

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201014

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20211126

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20211122BHEP

Ipc: A61P 35/02 20060101ALI20211122BHEP

Ipc: A61P 35/00 20060101ALI20211122BHEP

Ipc: A61K 31/435 20060101ALI20211122BHEP

Ipc: A61K 31/395 20060101ALI20211122BHEP

Ipc: A61K 31/33 20060101ALI20211122BHEP

Ipc: A61K 31/00 20060101ALI20211122BHEP

Ipc: A61K 31/47 20060101AFI20211122BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220625